Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 6425090

Next Previous
Drug Profile

PF 6425090

Alternative Names: Clostridium difficile vaccine - Pfizer; PF-06425090; PF-6425090; Toxoid-based Clostridium difficile vaccine - Pfizer

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Bacterial vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium difficile infections

Most Recent Events

  • 03 Mar 2022 Pfizer completes the phase III CLOVER trial in Clostridium difficile infection (Prevention) in USA, Japan, Canada, Argentina, Australia, Belgium, Bulgaria, Chile, Colombia, Czech Republic, Finland, France, Germany, Hungary, South Korea, Peru, Poland, Portugal, Slovakia, Spain, Sweden, Taiwan and United Kingdom (IM, Injection) (EudraCT2016-003866-14) (NCT03090191)
  • 01 Mar 2022 Safety and efficacy data from the phase III CLOVER trial in Clostridium difficile infections released by Pfizer
  • 03 Mar 2021 PF 6425090 is still in phase III trials for Clostridium difficile infections (In the elderly, Prevention) in USA (IM) (NCT03579459)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top